Drug Type Nanobody |
Synonyms Anti-TNFa and OX40L (Sanofi), Anti-TNFa/OX40L (Sanofi), SAR 442970 + [1] |
Target |
Action inhibitors |
Mechanism OX40L inhibitors(Tumor necrosis factor ligand superfamily member 4 inhibitors), TNF-α inhibitors(Tumor necrosis factor α inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 1 | Phase 2 | Canada | 28 Feb 2025 | |
Diabetes Mellitus, Type 1 | Phase 2 | Chile | 28 Feb 2025 | |
Glomerulosclerosis, Focal Segmental | Phase 2 | United States | 19 Dec 2024 | |
Glomerulosclerosis, Focal Segmental | Phase 2 | China | 19 Dec 2024 | |
Glomerulosclerosis, Focal Segmental | Phase 2 | Canada | 19 Dec 2024 | |
Glomerulosclerosis, Focal Segmental | Phase 2 | Chile | 19 Dec 2024 | |
Glomerulosclerosis, Focal Segmental | Phase 2 | France | 19 Dec 2024 | |
Glomerulosclerosis, Focal Segmental | Phase 2 | Germany | 19 Dec 2024 | |
Glomerulosclerosis, Focal Segmental | Phase 2 | Greece | 19 Dec 2024 | |
Glomerulosclerosis, Focal Segmental | Phase 2 | Italy | 19 Dec 2024 |